Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin: Matters Of The Heart

First Majestic Silver

Aimmune Therapeutics

Antero Midstream Partners

Exelixis

Intercept Pharma

Innovative Industrial Properties

Lovesac Company

Livongo Health Inc

Meet Group

Ping Identity Holding Corp

Pinterest

Redfin

Stitch Fix

StoneCo

Teva Pharmaceutical

Trupanion

Big gains could be just a click of the buy button away.

20 Stocks That Could Double Your Money in 2020

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov.  11, 2019  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 8:40 a.m. Greenwich Mean Time (GMT) / 3:40 a.m. Eastern Time (ET) in London, UK.

Amarin to Present at the Jefferies 2019 London Healthcare Conference

Prospects for Amarin's omega-3 drug seem strong, but does that make the stock a buy?

Is Amarin a Buy?

A positive outcome from an upcoming FDA advisory committee meeting is far from guaranteed.

6 Reasons Investors Are Nervous About Amarin's Big Date With the FDA

Investors didn't get what they wanted from Amarin's report, but better days could be close at hand.

Is Amarin a Buy After a Strong Q3?

Amarin Corporation PLC (AMRN) CEO John Thero on Q3 2019 Results - Earnings Call Transcript

Amarin beats estimates for both earnings and revenues in the third quarter of 2019. Shares up.

Amarin (AMRN) Beats Earnings & Revenues Estimates in Q3

Matinas BioPharma Hlds

Liver Therapy Forum weekly digest provides an overview of therapeutics in development for hypertriglyceridemia in 2019. The focus this week is on Matinas BioPharma.

Matinas BioPharma And Amarin In Hypertriglyceridemia: The Head-To-Head Phase 2 Study

Celsius Holdings

eHealth

Green Thumb Industries Inc.

Health Insurance Innovations

OptiNose

Zynerba Pharmaceuticals

Investors are looking for the stocks that have the potential to lift their portfolios to new heights.

7 Stocks to Buy With 100% Upside Potential

Amarin has a critical advisory committee meeting on Nov. 14 and a PDUFA on Dec. 28.

A Chat With John Thero, CEO Of Amarin

Heron Therapeutics

These two biotech stocks are poised for big gains next year.

2 Stocks That Could Double Your Money in 2020

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct.  17, 2019  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that an independent organization that evaluates pricing of prescription drugs has issued its final report assessing the cost-effectiveness of Vascepa® (icosapent ethyl) capsules. The final assessment confirms the cost-effectiveness of Vascepa across all the non-profit organization’s analyses, including its most stringent criteria.1

Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Patients at High Risk of Cardiovascular Events, such as Heart Attack, Stroke and Cardiac Death

An important regulatory milestone has been pushed back to late December, although investors will be awaiting voting results from a meeting in mid-November.

Why Amarin Investors Have Their Eyes on Nov. 14

This morning, I’m recommending a bullish call option on Amarin Corporation plc (NASDAQ:AMRN), the biopharmaceutical company.

This Biopharmaceutical Stock Looks Like a Steal

Acasti Pharma

The lucrative addressable market for therapeutics to treat hypertriglyceridemia is expected to increase in future years due to an unhealthy diet, sedentary lifestyles, and prevalence of obesity.

Acasti Pharma And Amarin In Severe Hypertriglyceridemia

Canopy Growth

American Airlines

AMC Entertainment

iRobot

Amarin, iRobot, Canopy Growth, AMC Entertainment and American Airlines were our top stock trades on Wednesday. 
The post 5 Top Stock Trades for Thursday: IRBT, AMRN, CGC appeared first on InvestorPlace.

5 Top Stock Trades for Thursday: IRBT, AMRN, CGC

ACADIA Pharma

These revenue-producing, possible acquisition candidates may be the right medicine to heal your portfolio.

3 Mid-Cap Biotech Stocks To Consider Buying Now

Amarin's Vascepa just might be a blockbuster.

How Fishy Is This Fish Oil Pill?

Celgene

Vertex Pharmaceuticals

These biotech stocks are great picks -- but for very different reasons.

3  Top Biotech Stocks to Buy Right Now

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept.  23, 2019  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present a general company update at the Cantor Global Healthcare Conference on Thursday, October 3, 2019, from 10:05-10:35 a.m. Eastern Time in New York City. A live audio webcast of the presentation will be available at:  http://www.amarincorp.com , and will be accessible at the same link for 30 days.

Amarin to Participate in the Cantor Global Healthcare Conference

News of AdComm and sNDA delay caused a significant drop in share price.

Amarin: A Favorable Trade Heading Into AdComm And SNDA

Millions of Patients on Statins with Elevated Triglycerides Are at Risk of Cardiovascular Events, Such as Heart Attack, Stroke or Death

National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins

Investors unloaded shares of this Irish biotech following a setback from the FDA.

Why Amarin Stock Dropped 19% in August

Biotech stocks tend to react badly to advisory committee meetings.

News for Amarin Corporation Plc Stock (AMRN)